OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - OmniAb, Inc. reported a quarterly loss of $0.17 per share, which aligns with the Zacks Consensus Estimate, and is an improvement from a loss of $0.19 per share a year ago [1] - The company posted revenues of $4.15 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 11.50%, but showing an increase from $3.8 million in the same quarter last year [2] - Over the last four quarters, OmniAb has surpassed consensus EPS estimates two times and has also topped consensus revenue estimates two times [2][3] Stock Performance - OmniAb shares have declined approximately 56.8% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The company's current Zacks Rank is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $5.55 million, and for the current fiscal year, it is -$0.62 on revenues of $24.17 million [7] - The outlook for the Medical - Drugs industry, to which OmniAb belongs, is currently in the top 26% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]